top of page

Boustead Client PetCure Oncology Regulation D 506(c) Offering Now Live

Boustead Securities client PetCure Oncology, LLC, a company providing veterinary cancer treatment utilizing noninvasive stereotactic radiosurgery (SRS) and stereotactic radiation therapy (SRT), announced that its offering pursuant to Regulation D 506(c) is now live at

”We believe the PetCure team has done a great job building the business to date to provide a valuable service to pet owners. We are privileged to help them with their private placement and future capital markets initiatives,” said Keith Moore, CEO of Boustead Securities, LLC.

Proceeds from the company’s planned $10,000,000 private placement are intended to be used to advance the efforts and network of PetCure Oncology to provide effective and compassionate veterinary cancer treatment and to aim to make SRS/SRT more accessible to pet owners. Currently fewer than 20 locations across the country offer SRS/SRT for pets. According to the National Cancer Institute, as of December 2017, twelve million new cancer diagnoses are made each year in dogs and cats, with cancer accounting for nearly 50% of all disease-related pet deaths each year.

PetCure Oncology’s national network of cancer care centers is designed to make potentially life-saving technology accessible to as many pets as possible. At each location, PetCure has partnered with one of the region’s leading veterinary specialty practices to provide both traditional cancer care and advanced radiation therapy, potentially giving pet owners one-stop access to comprehensive and collaborative cancer care.

Founder, CEO and pet-owner Scott Milligan was inspired to create PetCure Oncology after his family’s beloved golden retriever, Juliette, died from what he believed was treatable cancer.

Scott and PetCure are on a mission to provide pets and their families with broad access to advanced, noninvasive SRS treatment, and to connect them with their highly compassionate veterinary specialists to deliver medical care.

PetCure Oncology was created to help in the fight against the cancer diagnosis that is so devastating to pet families,” said Milligan. “We believe the technology and clinical teams that we have assembled to deliver this potentially life changing treatment are the very best in veterinary medicine. We are grateful to have an experienced and relentless partner like Boustead supporting us on our mission.”

Upon completion of the company’s private placement, the company plans to file for listing on a national exchange and undertake an initial public offering of its common stock shares. Learn more about the offering at

This press release is not a solicitation or offer to buy or sell securities. Investments may be speculative, illiquid and carry a risk of loss. Past performance is not indicative of future results. There is no guarantee that any specific outcome will be achieved.

About PetCure Oncology, LLC

Founded in 2014, PetCure Oncology’s mission is to provide pet families with support, knowledge and access to comprehensive and compassionate cancer care. PetCure Oncology has established a network of board-certified radiation oncologists and partnered with leading specialty animal hospitals across the country, providing a national network of comprehensive cancer centers with expertise in radiation oncology and stereotactic radiation (SRS/SRT), an advanced form of radiation therapy that may be effective in treating cancer. The first PetCure Oncology center opened in 2015 and the network aims to expand to seven centers in the fall of 2019 with additional sites under review. For more information, please visit

About Boustead Securities, LLC

Boustead Securities, LLC (“Boustead”) is an investment banking firm that executes and advises on IPOs, mergers and acquisitions, capital raises and restructuring assignments in a wide array of industries, geographies and transactions, for a broad client base. Boustead’s core value proposition is the ability to create opportunity through innovative solutions and tenacious execution. With experienced professionals in the United States, Boustead’s team moves quickly and provides a broad spectrum of sophisticated financial advice and services. Boustead is a majority owned subsidiary of Boustead & Company Limited, a diversified non-bank financial institution. For more information, please visit

About Sutter Securities Group, Inc.

Headquartered in Irvine, California, Sutter Securities Group, Inc. (“SSG”), founded in 2013, through its affiliates, is an innovator and investment banking solutions provider. SSG owns and operates Sutter Securities Clearing, LLC, and Sutter Securities Incorporated, FINRA member broker-dealers; Sutter Shareholder Services, LLC, a SEC-registered transfer agent; FlashFunders Funding Portal, LLC, a FINRA member funding portal; and Sutter Capital Management, Inc. Sutter Securities Group, through its affiliates, operates a U.S.-based online securities platform whose underlying technology and regulatory infrastructure are designed to enable issuers to engage in Regulation D, Regulation A (known as Reg A+), Regulation S, Regulation CF and fully registered S-1 and F-1 Initial Public Offerings in compliance with applicable federal, state and non-U.S. securities laws.   SSG is a majority owned subsidiary of Boustead & Company Limited, a diversified non-bank financial institution. Additional information is available at

Forward-Looking Statements

This announcement contains forward-looking statements. Forward-looking statements provide our current expectations or forecasts of future events. Forward-looking statements include statements about our expectations, beliefs, plans, objectives, intentions, assumptions and other statements that are not historical facts. Words or phrases such as “anticipate,” “believe,” “continue,” “estimate,” “expect,” “intend,” “may,” “ongoing,” “plan,” “potential,” “predict,” “project,” “will” or similar words or phrases, or the negatives of those words or phrases, may identify forward-looking statements, but the absence of these words does not necessarily mean that a statement is not forward-looking. Examples of forward-looking statements in this announcement include, but are not limited to, statements regarding our disclosure concerning the Company’s operations, cash flows, financial position and dividend policy.

21 views0 comments


bottom of page